I think this is actually a model that can in fact be propagated across multiple types of centers, as long as that communication is there. —Riad Salem, MD, MBA, FSIR, Co-principal investigator, EPOCH Trial

Warren Krackov, MD, FSIR, speaks with interventional radiologist and EPOCH Trial co-principal investigator Riad Salem, MD, MBA, FSIR, about the results of the trial and the potential for Y-90 treatment with TheraSpheres in patients with colorectal cancer metastases.

NOTE: EPOCH, an IDE pivotal trial, was a 428-patient, open-label, international, multicenter, phase 3 trial. EPOCH evaluated the safety and efficacy of TheraSphere Y-90 Glass Microspheres combined with second-line therapy (oxaliplatin- or irinotecan-based chemotherapy) in patients with mCRC of the liver. EPOCH met both primary endpoints of progression free survival and hepatic progression free survival. Learn more from Boston Scientific.

This episode was recorded on  Dec. 7, 2021.

Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.

(c) Society of Interventional Radiology.

Support the show